Emma I Andersson
Overview
Explore the profile of Emma I Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuesta-Mateos C, Fuentes P, Schrader A, Juarez-Sanchez R, Loscertales J, Mateu-Albero T, et al.
Biomark Res
. 2020 Oct;
8:54.
PMID: 33110606
Supplementary Information: accompanies this paper at 10.1186/s40364-020-00234-z.
2.
Andersson E, Bruck O, Braun T, Mannisto S, Saikko L, Lagstrom S, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32188095
Peripheral T-cell lymphomas (PTCL) are a heterogeneous, and often aggressive group of non-Hodgkin lymphomas. Recent advances in the molecular and genetic characterization of PTCLs have helped to delineate differences and...
3.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Adnan Awad S, Eldfors S, et al.
Nat Commun
. 2018 Apr;
9(1):1567.
PMID: 29674644
Aggressive natural killer-cell (NK-cell) leukemia (ANKL) is an extremely aggressive malignancy with dismal prognosis and lack of targeted therapies. Here, we elucidate the molecular pathogenesis of ANKL using a combination...
4.
He L, Tang J, Andersson E, Timonen S, Koschmieder S, Wennerberg K, et al.
Cancer Res
. 2018 Feb;
78(9):2407-2418.
PMID: 29483097
The molecular pathways that drive cancer progression and treatment resistance are highly redundant and variable between individual patients with the same cancer type. To tackle this complex rewiring of pathway...
5.
Lissina A, McLaren J, Ilander M, Andersson E, Lewis C, Clement M, et al.
Sci Rep
. 2018 Feb;
8(1):2534.
PMID: 29416058
CD8 T-cell expansions are the primary manifestation of T-cell large granular lymphocytic leukemia (T-LGLL), which is frequently accompanied by neutropenia and rheumatoid arthritis, and also occur as a secondary phenomenon...
6.
Andersson E, Coppe A, Bortoluzzi S
Oncotarget
. 2017 Dec;
8(55):93299-93300.
PMID: 29212142
No abstract available.
7.
Pietarinen P, Eide C, Ayuda-Duran P, Potdar S, Kuusanmaki H, Andersson E, et al.
Oncotarget
. 2017 Feb;
8(14):22606-22615.
PMID: 28186983
Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic phase (CP CML) respond to TKI therapy. However, there...
8.
Andersson E, Tanahashi T, Sekiguchi N, Gasparini V, Bortoluzzi S, Kawakami T, et al.
Blood
. 2016 Oct;
128(20):2465-2468.
PMID: 27697773
No abstract available.
9.
Rajala H, Olson T, Clemente M, Lagstrom S, Ellonen P, Lundan T, et al.
Haematologica
. 2014 Oct;
100(1):91-9.
PMID: 25281507
T-cell large granular lymphocytic leukemia and chronic lymphoproliferative disorder of natural killer cells are intriguing entities between benign and malignant lymphoproliferation. The molecular pathogenesis has partly been uncovered by the...
10.
Rajala H, Eldfors S, Kuusanmaki H, van Adrichem A, Olson T, Lagstrom S, et al.
Blood
. 2013 Apr;
121(22):4541-50.
PMID: 23596048
Large granular lymphocytic (LGL) leukemia is characterized by clonal expansion of cytotoxic T cells or natural killer cells. Recently, somatic mutations in the signal transducer and activator of transcription 3...